Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02256345
Other study ID # 01340
Secondary ID
Status Completed
Phase Phase 2
First received September 30, 2014
Last updated August 30, 2017
Start date January 2015
Est. completion date June 2016

Study information

Verified date August 2017
Source University of Pennsylvania
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will be performed to determine the safety, tolerability, and dose-response to inorganic nitrate on exercise capacity in HFpEF. There are two primary goals for this study:

1. Determine the population-specific pharmacokinetics and dose of KNO3 that can be safely given to subjects with HFpEF.

2. Determine if there is a dose-response effect of nitrate supplementation on exercise capacity, evidenced by peak oxygen consumption (peak VO2), and physiologic adaptations to exercise.


Description:

This study randomized subjects to either placebo (n=3) or KNO3 (n=9) given a sequential dosing regimen: 6 mmol twice daily for 1 week followed by dose escalation to 6 mmol thrice daily for 1 week). Although a primary goal of the study was to assess the safety of KNO3 and within-group changes in various end points in KNO3-treated subjects, a small number of placebo-treated (PB, n=3) subjects were included only to assess for any potential training effect on repeated exercise and Kansas City Cardiomyopathy Questionnaire (KCCQ) measurements. Potassium chloride, given in equivalent doses, was used as the PB to account for differences in blood pressure or flow that could be attributed to potassium.

The study was initially designed to be single-blinded to allow the principal investigator to be aware of arm allocation because of potential concerns for methemoglobinemia with drug administration. One investigator, who was the primary investigator responsible for supervising all visits and measurements during the study, remained blinded to treatment allocation throughout the entirety of the study. All physiological and imaging data were analyzed in a double-blind manner.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date June 2016
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. NYHA Class II-III symptoms.

2. LV EF > 50%.

3. Stable medical therapy for at least 1 month.

4. Evidence of significant diastolic dysfunction, meeting the European Society of Echocardiography criteria for HFpEF.

Exclusion Criteria

1. Any rhythm other than sinus with native conduction.

2. Inability to exercise.

3. Moderate or greater valvular disease.

4. Hypertrophic, infiltrative, or inflammatory cardiomyopathy.

5. Pericardial disease.

6. Current angina.

7. Acute coronary syndrome or coronary intervention within the past 2 months.

8. Primary pulmonary arteriopathy.

9. Clinically significant lung disease.

10. Ischemia on stress testing without subsequent revascularization.

11. Treatment with phosphodiesterase inhibitors that cannot be withheld.

12. Treatment with organic nitrates or allopurinol.

13. Significant liver disease impacting synthetic function or volume control.

14. Poor echocardiographic windows.

15. eGFR < 30 mL/min/m2 or Cr >2.5.

16. Current smoking.

17. Alcohol dependency.

18. History of Barret's esophagus.

19. G6PD deficiency

20. Methemoglobinemia - baseline methemoglobin level >3% prior to any study medication.

Study Design


Intervention

Drug:
KNO3
Active Comparator
KCl
Placebo Comparator

Locations

Country Name City State
United States Hospital of the University of Pennsylvania Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Peak Oxygen Uptake (VO2) From Baseline Upto 1 Week of Administration for Each Dose Peak oxygen uptake (VO2) defined as the average value obtained during the last 30 seconds of exercise. Baseline, end of week 1, end of week 2
Secondary Change in Vasodilatory Reserve for Each Dose Percent change in peak vascular resistance from rest to peak exercise Baseline, end of week 1, end of week 2
Secondary Change in Mitochondrial Oxidative Capacity for Each Dose Percent change in oxidative capacity (oxyhemoglobin levels) before and after occlusion Baseline, end of week 1, end of week 2
Secondary Change in Aortic Augmentation Index Percent change in augmentation index, whereas augmentation index at each time point (visit) is defined as the amplitude of the second peak to the first peak of the aortic pulse wave form multiplied by 100: augmentation index = (P2/P1)×100. Baseline, end of week 1, end of week 2
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy